Chronic hepatitis C infection and insulin resistance: Two best friends

Expert Review of Anti-Infective Therapy

Volumn 9, Issue 8, 2011, Pages 555-558

  Abenavoli, Ludovico ^a   Almasio, Piero L ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

HCV; insulin resistance; interferon resistance; liver steatosis

Indexed keywords

INSULIN SENSITIZING AGENT; PEGINTERFERON; PIOGLITAZONE; RIBAVIRIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ADJUVANT THERAPY; COMORBIDITY; DISEASE ASSOCIATION; DRUG RESPONSE; EDITORIAL; FATTY LIVER; HEPATITIS C; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; VIRUS ASSEMBLY; VIRUS REPLICATION;

FATTY LIVER; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE;

EID: 80051756864     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.11.72     Document Type: Editorial

References (26)

1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin. Liver Dis. 9, 383-398 (2005). (Pubitemid 40968202)
2. Reddy KR, Nelson DR, Zeuzem S. Ribavirin: Current role in the optimal clinical management of chronic hepatitis C. J. Hepatol. 50, 402-411 (2009). Overview of current therapeutic management of HCV chronic infection.
3. Jacobson I, Brown R, Freilich B et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis patients: A randomized trial. Hepatology 46, 971-981 (2007). (Pubitemid 350144761)
4. Vuppalanchi R, Chalasani N. Non-alcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 49, 306-317 (2009).
5. Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig. Liver Dis. 41, 615-625 (2009).
6. Abenavoli L, Aviello G, Capasso R et al. Milk thistle for non-alcoholic fatty liver disease treatment. Hepat. Mon. 11(3), 173-177 (2011). Analyzes the data of literature on liver steatosis pathogenesis and the efficacy of complementary medicine.
7. El-Zayadi AR. Hepatic steatosis: A benign disease or a silent killer. World J. Gastroenterol. 14(26), 4120-4126 (2008).
8. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J. Gastroenterol. 14, 6756-6765 (2006). (Pubitemid 44811395)
9. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: A meta-analysis of individual patient data. Gastroenterology 130, 1636-1642 (2006).
10. Arrese M, Riquelme A, Soza A. Insulin resistance, hepatic steatosis and hepatitis C: A complex relationship with relevant clinical implications. Ann. Hepatol. 9(S), 112-118 (2010).
11. Asselah T, Rubbia-Brandt L, Marcellin P et al. Steatosis in chronic hepatitis C: why does it really matter? Gut 55, 123-130 (2006). (Pubitemid 41820647)
12. Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122, 366-375 (2002). (Pubitemid 34116988)
13. Rubbia-Brandt L, Quadri R, Abid K et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J. Hepatol. 33, 106-115 (2000). (Pubitemid 30418941)
14. Lo Iacono O, Venezia G, Petta S et al. The impact of insulin resistance, serum adipocytokines and visceral obesity on steatosis and fibrosis in patients with chronic hepatitis C. Aliment. Pharmacol. Ther. 25(10), 1181-1191 (2007). (Pubitemid 46650297)
15. Douglas MW, George J. Molecular mechanisms of insulin resistance in chronic hepatitis C. World. J Gastroenterol. 15(35), 4356-4364 (2009). Authors summarize clinical associations between chronic hepatitis C and insulin resistance (IR) and analyze current knowledge regarding the molecular mechanisms that potentially mediate HCV-associated IR.
16. Sanyal AJ. Role of insulin resistance and hepatic steatosis in the progression of fibrosis and response to treatment in hepatitis C. Liver Int. 31(S1), 23-28 (2011).
17. Castera L, Hezode C, Roudot-Thoraval F et al. Effect of antiviral treatment on evolution of liver steatosis I patients with chronic hepatitis C: Indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut. 53, 420-424 (2004). (Pubitemid 38241341)
18. Kawaguchi T, Sata M. Importance of hepatitis C virus-associated insulin resistance: Therapeutic strategies for insulin sensitization. World J. Gastroenterol. 16(16), 1943-1952 (2010).
19. Conjeevaram HS, Fried MW, Jeffers LJ et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 131, 470-477 (2006). The primary goal of this study was to elucidate the mechanisms of antiviral resistance among patients who fail to respond to the optimal current regimen of therapy. (Pubitemid 44142464)
20. Romero-Gomez M, Del Mar Viloria M, Andrade RJ et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128, 636-641 (2005). (Pubitemid 40585366)
21. del Campo JA, López RA, Romero-Gómez M. Insulin resistance and response to antiviral therapy in chronic hepatitis C: Mechanisms and management. Dig. Dis. 28(1), 285-293 (2010).
22. Walsh MJ, Johnsson JR, Richardson MM et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55, 529-535 (2006).
23. Kawaguchi T, Yoshida T, Harada M et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 165, 1499-1508 (2004). (Pubitemid 39435150)
24. Miyaaki H, Ichikawa T, Nakao K et al. Predictive value of suppressor of cytokine signal 3 (SOCS3) in the outcome of interferon therapy in chronic hepatitis C. Hepatol. Res. 39, 850-855 (2009).
25. Shimomura I, Matsuda M, Hammer RE et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol. Cell. 6, 77-86 (2000).
26. Khattab M, Emad M, Abdelaleem A et al. Pioglitazone improves virological response to peginterferon a-2b/ ribavirin combination therapy in hepatitis C genotype 4 patients with insulin resistance. Liver Int. 30, 447-454 (2010). Demonstrates that pioglitazone addiction to the standard of care increases rates of sustained viral response in treatment-naive patients with HCV-4 and IR.